The firm, which is working to reaccelerate its test validation effort, incurred a loss of $5.4 million, or $.10 per share, slightly above the analysts' consensus estimate.
Researchers focused on candidate genes near expression quantitative trait loci identified by combining cancer susceptibility SNPs and available transcriptomic data.
In PLOS this week: variations in the way synonymous DNA codons are used in yeast, links between germline TP53 mutations and recurrent somatic mutations in bladder cancer, and more.
Re-expression of DUX4, which is normally silenced in somatic tissues, appeared to stymie MHC class I-related immune activity in several solid cancer types.
A proof-of-principle study suggests metabolite clusters may differ in non-small cell lung cancer patients depending on tumor type, disease stage, and overall survival trajectory.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
